Provided by Tiger Trade Technology Pte. Ltd.

Eupraxia Pharmaceuticals

8.42
+0.29003.57%
Post-market: 8.420.00000.00%16:00 EST
Volume:105.19K
Turnover:880.69K
Market Cap:426.46M
PE:-9.57
High:8.47
Open:8.14
Low:8.14
Close:8.13
52wk High:9.32
52wk Low:2.68
Shares:50.65M
Float Shares:39.63M
Volume Ratio:0.70
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8798
EPS(LYR):-0.7642
ROE:-61.02%
ROA:-36.21%
PB:7.31
PE(LYR):-11.02

Loading ...

Eupraxia Pharmaceuticals management to meet with Cantor

TIPRANKS
·
Feb 03

Eupraxia Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jan 15

Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald

TIPRANKS
·
Jan 15

H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
Jan 09

Eupraxia Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 09

Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus

Benzinga_recent_news
·
Jan 09

Eupraxia Pharmaceuticals Up Nearly 16%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk

Dow Jones
·
Nov 11, 2025

Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate

Benzinga
·
Nov 05, 2025

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 05, 2025

Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results

TIPRANKS
·
Nov 05, 2025

Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial

TIPRANKS
·
Oct 28, 2025

Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion

TIPRANKS
·
Oct 01, 2025

Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
Sep 30, 2025

Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

TIPRANKS
·
Sep 30, 2025

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

GlobeNewswire
·
Sep 30, 2025

Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

MT Newswires Live
·
Sep 24, 2025

Eupraxia Pharmaceuticals Down Over 7%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk

Dow Jones
·
Sep 24, 2025

Eupraxia Pharmaceuticals Prices $70 Million Public Offering

TIPRANKS
·
Sep 23, 2025

Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50

TIPRANKS
·
Sep 23, 2025

Eupraxia Pharmaceuticals Proposes Public Offering

MT Newswires Live
·
Sep 23, 2025